Xbrane Biopharma AB (XBRANE) — Working Capital to Net Assets Ratio
Xbrane Biopharma AB (XBRANE) has a Working Capital to Net Assets ratio of 41.0% as of June 2026. Working capital of Skr220.98 Million (current assets of Skr321.77 Million minus current liabilities of Skr100.79 Million) is measured against net assets of Skr538.85 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See defensive interval ratio of Xbrane Biopharma AB to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Xbrane Biopharma AB Working Capital to Net Assets (2012–2025)
This chart shows how Xbrane Biopharma AB's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 41.0%, reflecting working capital of Skr220.98 Million against net assets of Skr538.85 Million SEK. For the complete balance sheet picture, see total assets of Xbrane Biopharma AB.
Annual Working Capital to Net Assets for Xbrane Biopharma AB (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Xbrane Biopharma AB from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check how resilient are Xbrane Biopharma AB's assets to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 57.5% | Skr322.47 Million | Skr560.65 Million | Skr375.13 Million | Skr52.66 Million | ▲ +24.9 pp |
| 2024 | 32.6% | Skr67.96 Million | Skr208.54 Million | Skr605.90 Million | Skr537.94 Million | ▼ -46.3 pp |
| 2023 | 78.9% | Skr135.14 Million | Skr171.34 Million | Skr461.69 Million | Skr326.56 Million | ▲ +13.7 pp |
| 2022 | 65.2% | Skr276.95 Million | Skr424.89 Million | Skr513.52 Million | Skr236.57 Million | ▼ -13.9 pp |
| 2021 | 79.1% | Skr341.34 Million | Skr431.74 Million | Skr561.01 Million | Skr219.67 Million | ▲ +7.1 pp |
| 2020 | 72.0% | Skr185.49 Million | Skr257.71 Million | Skr374.48 Million | Skr188.99 Million | ▲ +13.2 pp |
| 2019 | 58.8% | Skr108.32 Million | Skr184.32 Million | Skr247.94 Million | Skr139.62 Million | ▲ +58.4 pp |
| 2018 | 0.3% | Skr277.00K | Skr83.07 Million | Skr161.66 Million | Skr161.38 Million | ▼ -11.2 pp |
| 2017 | 11.5% | Skr10.21 Million | Skr88.41 Million | Skr28.10 Million | Skr17.89 Million | ▼ -23.5 pp |
| 2016 | 35.1% | Skr37.64 Million | Skr107.30 Million | Skr43.53 Million | Skr5.88 Million | ▲ +68.7 pp |
| 2015 | -33.6% | Skr-15.97 Million | Skr47.51 Million | Skr7.43 Million | Skr23.40 Million | ▼ -131.5 pp |
| 2014 | 97.9% | Skr6.17 Million | Skr6.30 Million | Skr6.56 Million | Skr390.70K | ▼ -2.1 pp |
| 2013 | 100.0% | Skr8.69 Million | Skr8.69 Million | Skr9.20 Million | Skr505.44K | ▲ +0.0 pp |
| 2012 | 100.0% | Skr88.11K | Skr88.11K | Skr657.01K | Skr568.90K | — |